SCHEMBL24655830

SCHEMBL24655830

CN(C)C(=O)c1ncc(N)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 3/20 0.40
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
GCK P35557 3/20 0.33
CHEK2 O96017 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
USP7 Q93009 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15780518 0.80 APLNR (0.41) MAP4K1PARP1ALDH1A1KMT2AMEN1
SCHEMBL644275 0.78 ALDH1A1 (0.39) MAP4K1PARP1ALDH1A1KMT2AMEN1
SCHEMBL22048023 0.78 ALDH1A1 (0.33) MAP4K1PARP1ALDH1A1KMT2AMEN1
SCHEMBL31126503 0.75 GRM5 (0.33) MAP4K1PARP1ALDH1A1KMT2AMEN1
SCHEMBL23021755 0.75 FAAH (0.35) MAP4K1ALDH1A1KMT2AMEN1GCK
SCHEMBL26151714 0.75 EPHX2 (0.37) MAP4K1ALDH1A1KMT2AMEN1GCK
SCHEMBL28941018 0.75 MEN1 (0.37) MAP4K1PARP1ALDH1A1KMT2AMEN1
SCHEMBL9987095 0.75 P2RX7 (0.43) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL356561 0.74 PIK3CD (0.49) MAP4K1ALDH1A1KMT2AMEN1PIK3CD
SCHEMBL29002499 0.72 KMT2A (0.50) ALDH1A1KMT2AMEN1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-20250250259-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2025-08-07 US disclosed
US-12312341-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2025-05-27 US disclosed
US-20240400543-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-12-05 US disclosed
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. 2024-09-12 US disclosed
US-12084434-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-09-10 US disclosed
US-20240158376-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-05-16 US disclosed
CN-117813293-A Urea derivatives useful for the treatment of cancer 蝎子疗法股份有限公司 2024-04-02 CN disclosed
EP-4334298-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER Scorpion Therapeutics, Inc. (US) 2024-03-13 EP disclosed
US-20240076289-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-03-07 US disclosed
US-11897871-B1 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-02-13 US disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER PIK3CA, PIK3CG, PIK3CD MAP4K1 170/4885PARP1 3325/4885ALDH1A1 1105/4885
US-20240158376-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-11897871-B1 Methods for treating cancer PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-12312341-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-20240076289-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-20250250259-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-20240400543-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885
US-12084434-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 MAP4K1 556/4885PARP1 1346/4885ALDH1A1 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.